First, the good news: In a medical system that will literally either cut costs or die trying, anti-infectives are one of the best deals around. Read More
Kythera Biopharmaceuticals Inc. closed a Series D financing, landing $37.4 million to launch U.S. Phase III trials for its lead product, ATX 101. The first-in-class injectable is designed to reduce small fat deposits – including those under the chin and jawline, known as submental fat. Read More
WASHINGTON – Biopharma's part of the tab to reduce the nation's deficit includes a shorter exclusivity for biologics, steeper Medicare rebates and stiffer penalties under President Barack Obama's proposal to trim $3.5 trillion from the debt over the next 10 years. Read More
LONDON – Merck Serono SA picked up full rights to the Phase II-ready multiple sclerosis (MS) drug PI-2301 from the wreckage of Peptimmune Inc., for a very modest $1.5 million. Read More
Spinifex Pharmaceuticals Pty. Ltd., of Victoria, Australia, said the first patients have been treated in its Phase II trial of EMA401, an angiotensin II Type II receptor antagonist, in postherpetic neuralgia. Read More
The proposed merger of AMAG Pharmaceuticals Inc. and Allos Therapeutics Inc. has raised eyebrows from the start, but both firms remain committed to closing the deal, allowing neither criticism nor competing offers to stand in their way. Read More
RNL BIO Co. Ltd., of Germantown, Md., said its scientists collaborated with Samsung Bioscience Research Institute of Samsung Medical Center in Seoul, Korea, on a preclinical study using fat-derived adult stem cells to treat systemic lupus erythematosus (SLE). Read More
Tokai Pharmaceuticals Inc. is expected to announce Tuesday that it has raised $23 million in a Series D follow-on round to fund Phase IIb trials of triple-acting prostate cancer drug galeterone (TOK-001). Read More
